Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma

Internal Medicine

Volumn 52, Issue 1, 2013, Pages 63-70

  Muta, Tsuyoshi ^a   Miyamoto, Toshihiro ^a   Fujisaki, Tomoaki ^b   Ohno, Yuju ^c   Kamimura, Tomohiko ^d   Kato, Koji ^a   Takenaka, Katsuto ^a   Iwasaki, Hiromi ^a   Eto, Tetsuya ^e   Takamatsu, Yasushi ^f   Teshima, Takanori ^g   Akashi, Koichi ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b MATSUYAMA RED CROSS HOSPITAL   (Japan)

^c KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^d HARASANSHIN HOSPITAL   (Japan)

^e HAMANOMACHI HOSPITAL   (Japan)

^f FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^g HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autologous hematopoietic stem cell transplantation; Elderly patients with multiple myeloma; High dose melphalan

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; METHYLNITROSOUREA; PREDNISOLONE; THALIDOMIDE; VINCRISTINE;

AGED; ANOREXIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CARDIOTOXICITY; CD34 SELECTION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; ENDOMETRIUM CANCER; ENTERITIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEART EJECTION FRACTION; HUMAN; INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; PAROXYSMAL HEART ATRIUM FIBRILLATION; PNEUMOCYSTIS PNEUMONIA; PROSTATE CANCER; RETROSPECTIVE STUDY; SALVAGE THERAPY; SECOND CANCER; SEPSIS; STEM CELL MOBILIZATION; VIRUS REACTIVATION;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84871981152     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.8390     Document Type: Article

References (26)

1. Child JA, Morgan GJ, Davies FE, et al; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348: 1875-1883, 2003.
2. Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118: 4519-4529, 2011.
3. Dimopoulos M, Shimizu K, San Miguel J, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the International Myeloma Working Group. Blood 111: 4039-4047, 2008.
4. Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melpha lan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 94: 1248-1253, 1999.
5. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104: 3052-3057, 2004.
6. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 114: 600-607, 2001.
7. Facon T, Mary JY, Hulin C, et al; Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370: 1209-1218, 2007.
8. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106: 2912-2919, 2005.
9. Rajkumar SV, Harousseau JL, Durie B, et al; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117: 4691-4695, 2011.
10. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and metaanalysis of randomized controlled trials. Biol Blood Marrow Transplant 13: 183-196, 2007.
11. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: longterm results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23: 9227-9233, 2005.
12. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92: 3131-3136, 1998.
13. Attal M, Harousseau JL, Facon T, et al. Inter Groupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349: 2495-2502, 2003.
14. Cavo M, Tacchetti P, Patriarca F, et al. GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stemcell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet 376: 2075-2085, 2010.
15. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28: 2259-2266, 2010.
16. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93: 51-54, 1999.
17. Sirohi B, Powles R, Treleaven J, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 25: 533-539, 2000.
18. Reece DE, Bredeson C, Pérez WS, et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60 years of age. Bone Marrow Transplant 32: 1135-1143, 2003.
19. Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or = 65 years) myeloma patients: Comparison with younger patients treated on the same protocol. Bone Marrow Transplant 37: 917-922, 2006.
20. Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol 83: 614-617, 2008.
21. Bashir Q, Shah N, Parmar S, et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. Leuk Lymphoma 53: 118-122, 2012.
22. Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 101: 100-106, 2009.
23. Hamadani M, Kochuparambil ST, Osman S, et al. Intermediatedose versus low-dose cyclophosphamide and granulocyte colonystimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transplant 2012 Jan 14. [Epub ahead of print] PubMed PMID: 22248715.
24. Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 120: 413-423, 2003.
25. Tanimura A, Takeshita M, Sato A, et al. High-dose cyclophosphamide + G-CSF mobilization regimen have higher anti-myeloma effects than G-CSF alone regimen - Single institutional study in 147 myeloma patients from Japan ASH annual meeting abstracts. 118: 2007, 2011.
26. Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117: 3025-3031, 201.